The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial
Although the CR rate of children with idiopathic NS treated with RTX alone is significantly lower, the relapse rate among responders to RTX is also lower than that of the GC treatment.
Authors
- Weili Yan (ORCID: https://orcid.org/0000-0002-7633-7449)
- Chunyue Feng (ORCID: https://orcid.org/0000-0003-1565-2127)
- Ling-Fei Huang
- Siyi He (ORCID: https://orcid.org/0000-0001-7812-997X)
- Qiuyu Li (ORCID: https://orcid.org/0000-0003-4007-5536)
- Aiqin Sheng (ORCID: https://orcid.org/0000-0003-2700-4370)
- Yalan Dou (ORCID: https://orcid.org/0000-0002-4414-4730)
- Zhihong Lu (ORCID: https://orcid.org/0000-0001-5639-4705)
- Jingjing Wang (ORCID: https://orcid.org/0000-0003-3170-8952)
- Xiao‐Jing Zhang (ORCID: https://orcid.org/0000-0002-8271-7405)
- Haidong Fu (ORCID: https://orcid.org/0000-0001-9459-3078)
- Huijun Shen (ORCID: https://orcid.org/0000-0002-8083-5782)
- Jianhua Mao (ORCID: https://orcid.org/0000-0002-6076-3806)
- Jing-Li Zhao
- Fei Liu (ORCID: https://orcid.org/0009-0005-0576-440X)
Institutions
- National Clinical Research (US)
- Children's Hospital of Fudan University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1080/0886022x.2025.2499902
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86